CareDx Swings to Profit in Q3 on Strong Revenue Growth

Ticker: CDNA · Form: 10-Q · Filed: Nov 4, 2025 · CIK: 1217234

Sentiment: mixed

Topics: Biotechnology, Diagnostics, Transplant Medicine, Q3 Earnings, Revenue Growth, Net Income, Cash Flow, Litigation Risk

TL;DR

**CDNA's Q3 profit is a positive surprise, but watch that cash burn and litigation expense – it's a mixed bag for now.**

AI Summary

CareDx, Inc. (CDNA) reported a net income of $1.675 million for the three months ended September 30, 2025, a significant improvement from a net loss of $10.637 million in the same period of 2024. Total revenue increased by 20.7% to $100.055 million for the quarter, up from $82.883 million year-over-year. This growth was driven by a 18.7% increase in testing services revenue to $72.168 million, a 22.2% rise in product revenue to $12.478 million, and a 29.9% jump in patient and digital solutions revenue to $15.409 million. Despite the quarterly profit, the company still recorded a net loss of $17.246 million for the nine months ended September 30, 2025, though this was an improvement from a $35.148 million net loss in the prior year. Cash and cash equivalents decreased from $114.689 million at December 31, 2024, to $91.435 million at September 30, 2025, primarily due to $80.932 million in net cash used in financing activities, including $75.563 million for common stock repurchases. The company also recognized an accrued litigation settlement expense of $20.250 million as of September 30, 2025.

Why It Matters

CareDx's return to profitability in Q3 2025, driven by robust revenue growth across all segments, signals a potential turnaround for investors. The significant increase in testing services, product, and digital solutions revenue suggests strong market adoption for its transplant diagnostic solutions, which could enhance its competitive position against rivals in the precision medicine space. However, the substantial cash outflow for stock repurchases and a new $20.250 million litigation settlement expense introduce financial considerations that could impact future liquidity and investor confidence. Employees and customers benefit from a more financially stable company, potentially leading to continued innovation and service quality, but the overall market will watch if this quarterly profit can be sustained.

Risk Assessment

Risk Level: medium — CareDx reported a net income of $1.675 million for Q3 2025, a positive shift from a $10.637 million loss in Q3 2024. However, the company still has an accumulated deficit of $719.047 million as of September 30, 2025, and cash and cash equivalents decreased by $23.254 million since December 31, 2024. The addition of a $20.250 million accrued litigation settlement expense also presents a new financial obligation.

Analyst Insight

Investors should closely monitor CareDx's ability to sustain profitability and manage its cash flow, especially given the $75.563 million spent on stock repurchases and the new $20.250 million litigation settlement expense. While Q3's net income is a positive sign, further analysis of the underlying drivers and future guidance is crucial before making significant investment decisions.

Financial Highlights

debt To Equity
0.39
revenue
$100.055M
operating Margin
-0.2%
total Assets
$432.307M
total Debt
$121.167M
net Income
$1.675M
eps
$0.03
gross Margin
59.9%
cash Position
$91.435M
revenue Growth
+20.7%

Revenue Breakdown

SegmentRevenueGrowth
Testing services revenue$72.168M+18.7%
Product revenue$12.478M+22.2%
Patient and digital solutions revenue$15.409M+29.9%

Key Numbers

Key Players & Entities

FAQ

What were CareDx's key financial results for the third quarter of 2025?

CareDx, Inc. reported a net income of $1.675 million for the three months ended September 30, 2025, a substantial improvement from a net loss of $10.637 million in the same period of 2024. Total revenue increased by 20.7% to $100.055 million for the quarter, up from $82.883 million year-over-year.

How did CareDx's revenue streams perform in Q3 2025?

All three of CareDx's revenue streams showed strong growth in Q3 2025. Testing services revenue increased by 18.7% to $72.168 million, product revenue rose by 22.2% to $12.478 million, and patient and digital solutions revenue jumped by 29.9% to $15.409 million.

What is CareDx's cash position as of September 30, 2025?

As of September 30, 2025, CareDx had cash and cash equivalents of $91.435 million. This represents a decrease from $114.689 million at December 31, 2024, primarily due to significant cash used in financing activities.

Did CareDx engage in any share repurchases during the nine months ended September 30, 2025?

Yes, CareDx repurchased and retired common stock totaling $75.563 million during the nine months ended September 30, 2025. This activity contributed to the net cash used in financing activities.

What is the significance of the accrued litigation settlement expense for CareDx?

CareDx recognized an accrued litigation settlement expense of $20.250 million as of September 30, 2025. This new liability indicates a significant financial obligation related to legal matters, which could impact future financial performance and liquidity.

What was CareDx's net loss for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, CareDx reported a net loss of $17.246 million. While still a loss, this is an improvement compared to the $35.148 million net loss reported for the same period in 2024.

How many shares of common stock were outstanding for CareDx as of October 30, 2025?

As of October 30, 2025, there were 51,432,639 shares of CareDx's Common Stock issued and outstanding.

What are CareDx's primary business focuses?

CareDx is a precision medicine company focused on the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers. They offer testing services like AlloSure Kidney and AlloMap Heart, products for pre-transplant matching, and digital transplant solutions.

What was the change in CareDx's total assets from December 31, 2024, to September 30, 2025?

CareDx's total assets decreased from $491.050 million at December 31, 2024, to $432.307 million at September 30, 2025. This reduction of $58.743 million was influenced by decreases in cash, marketable securities, and accounts receivable.

What is CareDx's current status regarding its internal control over financial reporting?

CareDx has identified a material weakness in its internal control over financial reporting that was not remediated as of September 30, 2025. The company is working on its ability to remediate this material weakness.

Risk Factors

Industry Context

CareDx operates in the specialized field of transplant diagnostics and digital health solutions. The industry is characterized by rapid technological advancements, a strong focus on clinical validation, and a complex regulatory environment. Key competitors often focus on specific areas like organ rejection monitoring or patient management post-transplant. Trends include the increasing adoption of non-invasive testing methods and integrated digital platforms to improve patient outcomes and streamline healthcare processes.

Regulatory Implications

As a provider of diagnostic tests and digital health solutions, CareDx is subject to rigorous regulatory oversight from agencies like the FDA. Any changes in regulatory requirements, compliance issues, or delays in product approvals could significantly impact the company's operations, market access, and financial performance. The recent recognition of a substantial litigation settlement expense also highlights potential legal and regulatory risks.

What Investors Should Do

  1. Monitor the impact of the $20.250M litigation settlement on future cash flows and profitability.
  2. Analyze the sustainability of revenue growth, particularly in the high-growth Patient and Digital Solutions segment.
  3. Evaluate the company's strategy regarding cash deployment, especially the significant common stock repurchases.
  4. Assess the trend in operating expenses, particularly the increase in sales and marketing, against revenue growth.

Key Dates

Glossary

Accumulated deficit
The cumulative net losses of a company since its inception, minus any cumulative net profits. It represents a historical shortfall in earnings. (Indicates that CareDx has historically incurred more expenses than revenues, with a current accumulated deficit of $719.047 million.)
Accrued litigation settlement expense
An expense that has been incurred but not yet paid, related to a legal settlement. It is recognized as a liability on the balance sheet. (A new liability of $20.250 million recognized as of September 30, 2025, impacting the company's current liabilities and financial position.)
Common stock repurchases
When a company buys back its own shares from the open market, reducing the number of outstanding shares. (CareDx used $75.563 million for common stock repurchases in the nine months ended September 30, 2025, significantly contributing to cash outflow.)
Operating leases right-of-use assets
An asset recognized under accounting standards for leases, representing the right to use an asset over the lease term. (CareDx has $24.047 million in operating lease right-of-use assets as of September 30, 2025, reflecting its commitments for leased properties or equipment.)
Marketable securities
Investments in financial instruments that are readily convertible to cash, such as stocks and bonds. (CareDx held $102.782 million in marketable securities as of September 30, 2025, which can be a source of liquidity.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, CareDx has demonstrated significant top-line growth, with total revenue increasing by 9.8% to $271.419 million. This growth has translated into a substantial improvement in profitability, with the net loss narrowing from $35.148 million to $17.246 million. However, the company's cash position has declined by $23.254 million, largely due to substantial stock repurchases, and a new $20.250 million litigation settlement expense has been recognized, adding a new risk factor.

Filing Stats: 4,688 words · 19 min read · ~16 pages · Grade level 19.1 · Accepted 2025-11-04 16:13:11

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 5

Unaudited Condensed Consolidated Financial Statements

Item 1. Unaudited Condensed Consolidated Financial Statements 5 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Comprehensive Income (Loss) 7 Condensed Consolidated Statements of Stockholders' Equity 8 Condensed Consolidated Statements of Cash Flows 10 Notes to Unaudited Condensed Consolidated Financial Statements 11

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 29

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 38

Controls and Procedures

Item 4. Controls and Procedures 38

OTHER INFORMATION

PART II. OTHER INFORMATION 40

Legal Proceedings

Item 1. Legal Proceedings 40

Risk Factors

Item 1A. Risk Factors 40

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 73

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 73

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 73

Other Information

Item 5. Other Information 73

Exhibits

Item 6. Exhibits 74

Signatures

Signatures 75 2 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements contained in this Quarterly Report on Form 10-Q other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words "believe," "may," "will," "potentially," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "target," "predict," "expect" and the negative and plural forms of these words and similar expressions are intended to identify forward-looking statements. "CareDx" or the "Company" or "we" or "us" or "our" as used in the Quarterly Report on Form 10-Q refer to CareDx, Inc. and its subsidiaries. These forward-looking statements may include, but are not limited to, statements concerning the following: our ability to generate revenue and increase the commercial success of our current and future testing services, products and patient and digital solutions; our ability to obtain, maintain and expand reimbursement coverage from payers for our current and other future testing services, if any; our plans and ability to continue updating our testing services, products and patient and digital solutions to maintain our leading position in transplantation; the outcome or success of our clinical trial collaborations and registry studies; the favorable review of our testing services and product offerings, and our future solutions, if any, in peer-reviewed publications; our ability to obtain additional financing on terms favorable to us, or at all; our anticipated cash needs and our antici

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS CareDx, Inc. Condensed Consolidated Balance Sheets (Unaudited) (In thousands, except share data) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 91,435 $ 114,689 Marketable securities 102,782 145,964 Accounts receivable 47,844 64,605 Inventory 28,328 19,503 Prepaid and other current assets 29,891 7,071 Total current assets 300,280 351,832 Property and equipment, net 30,845 33,552 Operating leases right-of-use assets 24,047 24,340 Intangible assets, net 33,446 38,184 Goodwill 40,336 40,336 Restricted cash 551 585 Other assets 2,802 2,221 Total assets $ 432,307 $ 491,050 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 11,597 $ 7,686 Accrued compensation 23,237 38,333 Accrued litigation settlement expense 20,250 — Accrued and other liabilities 43,960 43,352 Total current liabilities 99,044 89,371 Deferred tax liability 117 164 Contingent consideration 160 174 Operating lease liability, less current portion 21,212 22,263 Other liabilities 634 645 Total liabilities 121,167 112,617 Commitments and contingencies (Note 8) Stockholders' equity: Preferred stock: $ 0.001 par value; 10,000,000 shares authorized at September 30, 2025 and December 31, 2024; no shares issued and outstanding at September 30, 2025 and December 31, 2024 — — Common stock: $ 0.001 par value; 100,000,000 shares authorized at September 30, 2025 and December 31, 2024; 51,407,335 and 54,771,203 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 51 51 Additional paid-in capital 1,036,091 1,013,193 Accumulated other comprehensive loss ( 5,955 ) ( 8,569 ) Accumulated deficit ( 719,047 ) ( 626,242 ) Total stockholders' equity 311,140 378,433 Total liabilities and stockholders' equity $ 432,307 $ 491,050 The accompanying notes are an integral part of these unaudited condensed consolidated financi

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing